1,254 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by GraniteShares Advisors LLC

GraniteShares Advisors LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 1,254 shares of the biotechnology company’s stock, valued at approximately $442,000.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. World Investment Advisors LLC bought a new stake in shares of United Therapeutics during the third quarter worth approximately $139,206,000. FMR LLC raised its stake in shares of United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the last quarter. AustralianSuper Pty Ltd increased its stake in United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after purchasing an additional 161,751 shares in the last quarter. Assetmark Inc. increased its stake in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent analyst reports. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH upped their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Down 0.2 %

United Therapeutics stock opened at $357.50 on Wednesday. The stock has a market capitalization of $15.96 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The company has a 50 day moving average of $361.95 and a 200-day moving average of $361.11.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 255 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,164 shares of company stock worth $45,278,893. 11.90% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.